Diabetes Leadership Edge: Advancing PA Leadership in the Management of Type 2 Diabetes | Module 6 - The Convergence of Cardiovascular Risk Reduction and Glucose Management in Patients with Type 2 Diabetes
This interactive module explores the relationship between type 2 Diabetes (T2D) and cardiovascular disease. Also available The Convergence of Cardiovascular Risk Reduction and Glucose Management in Patients with Type 2 Diabetes a supplement to JAAPA.

Module 6 - The Convergence of Cardiovascular Risk Reduction and Glucose Management in Patients with Type 2 Diabetes


Ji Chun, PA-C, MPAS, BC-ADM; Sondra DePalma, DHSc, PA-C, DFAAPA

This activity explores the relationship between type 2 Diabetes (T2D) and cardiovascular disease and is part of AAPA’s curriculum known as Diabetes Leadership Edge.

Educational Objectives

At the conclusion of this activity, you should be able to:
  • Describe the pathophysiology of type 2 diabetes and CVD.
  • Review the results of previous strategies addressing CV risk through glucose control.
  • Identify the role of the rosiglitazone controversy in ushering in a new era of CV outcome studies mandated by the Food and Drug Administration (FDA) for type 2 diabetes agents.
  • Summarize the results of cardiovascular outcome trails (CVOTs) of new diabetes agents.
  • Differentiate among agents based on their CV profile.
  • Select an appropriate second agent based on a patient's CV risk profile.

Accreditation Statement


This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation. Approval is valid until January 31, 2020.

Disclosure Policy Statement

It is the policy of AAPA to require the disclosure of the existence of any financial interest or any other relationship a faculty member has with the commercial interest of any commercial product discussed in an educational supplement. The participating faculty reported the following:

Faculty

Ji Chun, PA-C, MPAS, BC-ADM
Optum Medical Partners: Endocrinology
Orange County, CA
President, American Society of Endocrine Physician Assistants (ASEPA)
Editorial Board, Clinician Reviews
Disclosures: Consultant, Advisory Board- Intarcia, Novo Nordisk, Mannkind, Merck; Speaker’s Bureau - AstraZeneca

Sondra DePalma, DHSc, PA-C, DFAAPA
Director of Regulatory and Professional Practice
American Academy of PAs
UPMC PinnacleHealth CardioVascular Institute: Cardiology
Harrisburg, PA
Nothing to disclose

AAPA and the faculty acknowledge the valuable contributions of our medical writer, Anne Greenberg, BSJ Executive Vice President of Health & Medical Multimedia to the development of this CME activity.
Nothing to disclose

Disclaimer

The opinions and comments expressed by faculty and other experts, whose input is included in this program are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program, including indications, contraindications, warnings, and adverse reactions, and dosage before administering to patients.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Novo Nordisk Inc. and AstraZeneca Pharmaceuticals LP.

AAPA offers no returns or refunds for online CME activities purchased through the AAPA store. All sales are final.


Type:     Internet Activity (Enduring Material)
93 Registered Users